A recent systematic review showed that GLP-1 agonists alleviate depression and promote cognition in mood disorders, reduce the severity of alcohol and other substance use disorders, decrease binge eating behaviors, and improve cognitive functioning in schizophrenia (Tempia Valenta et al., 2024). This evidence concerns the gene GLP1R and depressive disorder.